 |
TSO3: Another Sale of the 125L Ozone Sterilizer in the United States and implementation of an Employee Stock Purchase Plan.June 29, 2007Québec City, June 29, 2007 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces another sale of its 125L Ozone Sterilizer to an American hospital.“With a direct and growing sales force, this new sale shows that our commercialization strategy is working. This sale also illustrates the constantly growing interest for the 125L Ozone Sterilizer” declared Jocelyn Vézina, the Chief Executive Officer of TSO3 Inc. “We are convinced that our Ozone Sterilization technology which is economical, environmentally responsible and easy to use, is the future of low temperature sterilization, a promising future” he concluded. Stock Purchase Plan TSO3 announces the implementation of a Stock Purchase Plan for its managers and employees. According to the Plan, TSO3’s managers and employees have the opportunity to contribute to the Plan up to 5 % of their salary. TSO3 will participate by an amount equal to 50 % of the employee contribution. This amount will be monthly deposited with a brokerage firm which will buy TSO3 shares, at market price, at the end of each month. “We are really pleased with the implementation of this Plan, which will allow TSO3’s employees to participate in our success. Beside the participation of the four managers, the Plan’s subscription campaign went really well. Close to 45 % of the employees are participating, and the majority comes from the clinical staff and the sales and marketing department” declared Jocelyn Vézina. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization by Health Canada and by the U.S. Food and Drug Administration (FDA). TSO3 currently has more than 60 employees, 25 of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Mathieu Claise Interim Director, Corporate Communications and Investor Relations 418 651-0003, Ext. 237 Email: ir@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
